EBS FY 2023 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$446M

FY 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$1.0B-6.1% YoY

Gross Profit

$360M34.3% margin

Operating Income

-$726M-69.2% margin

Net Income

-$761M-72.5% margin

EPS (Diluted)

$-14.85

Cash Flow

Operating Cash Flow

-$206M

Free Cash Flow

-$258M

Stock-Based Comp.

$23M

Balance Sheet

Total Assets

$1.8B

Total Liabilities

$1.2B

Stockholders' Equity

$649M

Cash & Equivalents

$112M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.0B	$1.1B	-6.1%
Gross Profit	$360M	$473M	-23.9%
Operating Income	-$726M	-$170M	-327.3%
Net Income	-$761M	-$212M	-259.4%